Showing 231-240 of 4005 results for "".
Quadrivalent Vaccine Against HPV
https://reachmd.com/programs/clinicians-roundtable/quadrivalent-vaccine-against-hpv/581/Dr. Kevin Ault discusses his latest publication in The New England Journal of Medicine on the HPV vaccine.Functional Magnetic Resonance Imaging
https://reachmd.com/programs/clinicians-roundtable/functional-magnetic-resonance-imaging/502/Keith Thulborn, M.D., Ph.D. discusses how fMRI works and it's latest uses.Research Findings Presented at Digestive Disease Week 2010
https://reachmd.com/programs/conference-coverage/research-findings-presented-at-digestive-disease-week-2010/5627/Listen to the latest research findings presented at Digestive Disease Week 2010. This conference was held May 1-6 in New Orleans.Highlights from the Crohn’s & Colitis Foundation Perspectives Series
https://reachmd.com/programs/crohns-colitis-foundation-perspectives/highlights-from-the-crohns-colitis-foundation-perspectives-series/10169/Hear from experts, patients, and caregivers as they discuss the latest in IBD in the Crohn’s & Colitis Foundation Perspectives series.Insights and Updates: New Data on Next-Generation Retinal Treatments
https://reachmd.com/programs/cme/Insights-and-Updates-New-Data-on-Next-Generation-Retinal-Treatments/36107/Join our faculty as they discuss the latest clinical and real-world data surrounding faricimab, aflibercept 8 mg, and the PDS with ranibizumab.Exploring Updates in the C. Difficile Treatment Landscape
https://reachmd.com/programs/gi-insights/exploring-updates-in-the-c-difficile-treatment-landscape/14628/From probiotics to proton pump inhibitors, learn more about the latest treatment considerations for C. difficile infection.Rethinking MacTel: Cell-based Insights for Vision Preservation
https://reachmd.com/programs/cme/Rethinking-MacTel-Cell-Based-Insights-for-Vision-Preservation/35524/Catch up on the latest information on the management of macular telangiectasia type 2 (MacTel) with a new encapsulated cell therapy, revakinagene taroretcel.FcRn Inhibitors: A Potential New Targeted Therapy Option
https://reachmd.com/programs/neurofrontiers/tbd/30071/Here’s how FcRn inhibitors can offer a new approach to generalized myasthenia gravis treatment.Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology
https://reachmd.com/programs/cme/mechanism-driven-gmg-therapy-fcrn-antagonists-and-the-rise-of-precision-neurology/36277/Review FcRn antagonists in gMG, including mechanisms, pivotal trials, and strategies for integrating novel therapies into personalized care.Drugmakers' Foray into the Combination Pill Market
https://reachmd.com/programs/clinicians-roundtable/drugmakers-foray-into-the-combination-pill-market/3523/Why take two pills when you can just take one? Welcome to the latest phenomenon in healthcare: combination pills. Tim Walbert, president and chief executive officer of Horizon Therapeutics, tells host Bruce Japsen about the drug industry's push toward combining two or more treatments into one pill,